In This Edition
- Cost sharing for prescription medications increases consumption of more costly healthcare services
- Community-acquired pneumonia core measures can lead to unintended consequences
- Prophylactic revascularization has no clear benefit for high-risk patients undergoing vascular surgery
- Aspirin resistance correlates with adverse clinical events
- Low-molecular-weight heparin appears to have greater efficacy as a prophylactic agent against deep-vein thrombosis and pulmonary embolism
- Antipsychotic medications appear to be associated with increased risk of death in demented patients
- Anticoagulation plus antiplatelet therapy fails to show benefit for peripheral arterial disease
- Transient atrial fibrillation following myocardial infarction increases the risk of recurrence and stroke
Background: Insurers are increasingly using financial mechanisms to affect pharmaceutical usage. These practices may affect medication use and health outcomes in ways that are poorly defined and difficult to detect.
Study design: Literature review
Synopsis: There are numerous structures for drug-cost sharing, and this study evaluated co-payments, tiers/co-insurance, benefit caps, formulary limitations, and reference pricing strategies for their effect on prescription drug usage and healthcare outcomes.